Spots Global Cancer Trial Database for The Second Multicenter Hemophilia Cohort Study
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Second Multicenter Hemophilia Cohort Study
Official Title: The Second Multicenter Hemophilia Cohort Study
Study ID: NCT00341705
Interventions
Study Description
Brief Summary: The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV). The vast majority will have been infected with HCV, and approximately 1/3 will have been infected with human immunodeficiency virus (HIV). Primary objectives are to quantify the rates of liver decompensation, hepatocellular carcinoma, and non-Hodgkin lymphoma and to evaluate candidate clinical, genetic, virologic, serologic and immunologic markers that are likely to be on the causal pathway for these conditions. Candidate clinical and laboratory markers will be examined longitudinally to define changes over time and their relationships to one another. Collaborative studies will focus on genome scanning and evaluation of candidate genetic loci for susceptibility or resistance to HCV and HIV infections or to the diseases that result from these infections. Additional studies will identify response and complication rates of various anti-HCV and anti-HIV regimens in the setting of comprehensive clinical care of persons with hemophilia.
Detailed Description: The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV). The vast majority will have been infected with HCV, and approximately 1/3 will have been infected with human immunodeficiency virus (HIV). Primary objectives are to quantify the rates of liver decompensation, hepatocellular carcinoma, and non-Hodgkin lymphoma and to evaluate candidate clinical, genetic, virologic, serologic and immunologic markers that are likely to be on the causal pathway for these conditions. Candidate clinical and laboratory markers will be examined longitudinally to define changes over time and their relationships to one another. Collaborative studies will focus on genome scanning and evaluation of candidate genetic loci for susceptibility or resistance to HCV and HIV infections or to the diseases that result from these infections. Additional studies will identify response and complication rates of various anti-HCV and anti-HIV regimens in the setting of comprehensive clinical care of persons with hemophilia.
Eligibility
Minimum Age: 13 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Arizona, Tucson, Arizona, United States
University of California, Davis, Davis, California, United States
Children's Hospital of Orange County, Orange, California, United States
University of California, San Francisco, San Francisco, California, United States
University of Colorado, Denver, Colorado, United States
Christiana Hospital, Wilmington, Delaware, United States
Georgetown University, Washington, District of Columbia, United States
Childrens National Medical Center, Washington, District of Columbia, United States
Emory University, Atlanta, Georgia, United States
University of Illinois, Chicago, Illinois, United States
Childrens Memorial Hospital, Chicago, Chicago, Illinois, United States
St. Vincent's Hospital, Indianapolis, Indiana, United States
Tulane University, New Orleans, Louisiana, United States
Wayne State University Hutzel Hospital, Detroit, Michigan, United States
University of Minnesota, Minneapolis, Minnesota, United States
University of Mississippi, Jackson, Mississippi, United States
St. Louis University, Saint Louis, Missouri, United States
University of New Mexico, Albuquerque, New Mexico, United States
University of Buffalo, Buffalo, New York, United States
North Shore Long Island Jewish Health System, Lake Success, New York, United States
Cornell University, New York, New York, United States
Mt. Sinai Medical Center, New York, New York, United States
University of North Carolina, Chapel Hill, North Carolina, United States
Wake Forest University, Winston-Salem, North Carolina, United States
Childrens Hospital, Cinncinati, Cincinnati, Ohio, United States
University of Cincinnati, Cincinnati, Ohio, United States
Ohio State University, Columbus, Ohio, United States
Wright State University, Dayton, Ohio, United States
University of Oklahoma, Oklahoma City, Oklahoma, United States
Milton Hershey Medical Center, Hershey, Pennsylvania, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Palmentto Health Alliance, Columbia, South Carolina, United States
University of Tennessee, Memphis, Tennessee, United States
Vanderbilt University, Nashville, Tennessee, United States
University of Texas, Houston, Houston, Texas, United States
University of Texas, San Antonio, San Antonio, Texas, United States
University of Utah, Salt Lake City, Utah, United States
Childrens Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Hospital Brigadeiro, Sao Paulo, , Brazil
University of Sao Paulo, Sao Paulo, , Brazil
South East Health Care Corporation, New Brunswick, , Canada
Hospices Civils de Lyon, Lyons, , France
University of Bonn, Bonn, , Germany
Laikon General Hospital of Athens, Athens, , Greece
University of Florence, Florence, , Italy
University de Milano, Milan, , Italy
Karolinska Institute St. Gorans Hospital, Stockholm, , Sweden
Contact Details
Name: James J Goedert, M.D.
Affiliation: National Cancer Institute (NCI)
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
